For persistence, results from the NMA from RCTs showed that ZOL users may be less likely to dropout from trials at 12 months, although these effects were marginally non-significant.
← all excerpts
Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis.
1
—
—